Antihyperlipidemic Therapies Targeting PCSK9

@article{Weinreich2014AntihyperlipidemicTT,
  title={Antihyperlipidemic Therapies Targeting PCSK9},
  author={Michael Weinreich and William H. Frishman},
  journal={Cardiology in Review},
  year={2014},
  volume={22},
  pages={140–146}
}
Hyperlipidemia is a major cause of cardiovascular disease despite the availability of first-line cholesterol-lowering agents such as statins. A new therapeutic approach to lowering low-density lipoprotein-cholesterol (LDL-C) acts by blocking LDL-receptor degradation by serum proprotein convertase subtilisin kexin 9 (PCSK9). Human monoclonal antibodies that target PCSK9 and its interaction with the LDL receptor are now in clinical trials (REGN727/SAR23653, AMG145, and RN316). These agents are… 
Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy
TLDR
These novel agents are generally well tolerated and once long-term safety data are available they appear promising therapeutic platforms for the treatment of patients with hypercholesterolaemia at risk for or with CVD not controlled by conventional therapies.
Vaccines Targeting PSCK9 for the Treatment of Hyperlipidemia
TLDR
This work aims to provide an overview of PCSK9 vaccines and their potential clinical benefit, and indicates that Administration of active vaccination instead of passive immunization with anti-PCSK9 antibodies may be an effective way of controlling blood cholesterol levels.
New and emerging lipid-modifying drugs to lower LDL cholesterol
TLDR
PCSK9 inhibitors, bempedoic acid, inclisiran, ANGPTL3 inhibitors, PPARβ/δ agonists and LXR agonists are novel or upcoming LDL-C-lowering agents that have shown promising beneficial results.
Alirocumab in the Treatment of Hypercholesterolemia
TLDR
Alirocumab is a PCSK9 inhibitor, which was recently approved by the Food and Drug Administration as an adjunct to diet and maximally tolerated statin therapy for treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL-C levels.
PCSK9 Inhibitors: An Innovative Approach to Treating Hyperlipidemia
TLDR
They have been shown to produce significant reductions in LDL and are well tolerated in clinical studies, but they are very costly when compared with statins, the current mainstay of hyperlipidemia treatment.
PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
TLDR
The role of PCSK9 in lipid homeostasis was elucidated, the effect ofPCSK9 on atherosclerosis was highlighted, and contemporary therapeutic techniques that focused on PCSK 9 were summarized.
Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
TLDR
Interventions targeting PCSK9 by reducing its expression may lead to significant reductions of LDL-cholesterol and possibly decrease cardiovascular risk, according to the current clinical and scientific data.
New and Emerging LDL Cholesterol–Lowering Drugs
TLDR
This review aims to provide the current evidence regarding the newly approved LDL-C-lowering agents, as well as the clinical and scientific data pertaining to promising new and emerging cholesterol lowering drugs on the horizon.
The Allergenic Role of the Drug Excipient in a Case of Allergy in Pcsk-9 Inhibitor
TLDR
A case of allergy on Alirocumab only, one of PCSK-9 inhibitors is presented, which shows the ability of blocking this enzyme to lower blood LDL concentrations.
...
1
2
3
4
...

References

SHOWING 1-10 OF 89 REFERENCES
Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Low-density lipoprotein cholesterol reduction by inhibition of PCSK9
  • E. Stein
  • Biology
    Current opinion in lipidology
  • 2013
TLDR
Provided these compounds continue to exhibit an acceptable safety profile in ongoing phase 3 trials they will be as crucial to LDL-C control and reduction of cardiovascular disease, as statins.
The promises of PCSK9 inhibition
TLDR
The discovery of PCSK9, its original mode of action as a secreted inhibitor of the LDL receptor, as well as its genetic regulation by statins are summarized.
Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
TLDR
In this phase 2 study in statin-intolerant patients, subcutaneous administration of a monoclonal antibody to PCSK9 significantly reduced LDL cholesterol levels and was associated with short-term tolerability.
Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia
  • R. Rosenson
  • Biology, Medicine
    Expert review of cardiovascular therapy
  • 2003
TLDR
Rosuvastatin has the longest terminal half-life of the statins and is only minimally metabolized by the cytochrome P450 (CYP 450) enzyme system with no significant involvement of the 3A4 enzyme and the absence of clinically significant drug interactions between rosuvastatin and other drugs known to inhibit CYP 450 enzymes.
The PCSK9 decade
TLDR
Initial data from investigations of PCSK9 inhibition in humans are promising and indicate that PCSK 9 inhibition may be a viable new therapeutic option for the treatment of dyslipidemia and associated cardiovascular diseases.
Current overview of statin-induced myopathy.
  • R. Rosenson
  • Biology, Medicine
    The American journal of medicine
  • 2004
...
1
2
3
4
5
...